A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Jazz Pharmaceuticals, a leading global biopharmaceutical company, recorded an astonishing $1.8 billion in revenue this year from the sales of Gamma Hydroxybutyrate (GHB).
Researchers from The University of Queensland have discovered the active compound from Hericium erinaceus – otherwise known as Lion’s mane – that boosts nerve growth and...
Irwin Naturals has signed a Letter of Intent entering into a partnership with Braxia Scientific – which is developing innovative ketamine and psilocybin treatments for mental...
HMNC Brain Health and Develco Pharma have announced promising top-line results from the Phase II proof-of-concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01)...
The trial MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has advanced to the next implementation phase.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Psyched Wellness and the National Research Council of Canada (NRC) have announced preliminary data from studies of the neuroprotective and anti-inflammatory properties of AME-1.
The first patient has now been enrolled on to the Entheon Biomedical Phase 1 Study of DMT.